Australia markets closed

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.1900-0.0800 (-3.52%)
At close: 04:00PM EDT
2.2200 +0.03 (+1.37%)
After hours: 06:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.2700
Open2.2200
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1800 - 2.3000
52-week range1.4900 - 20.6600
Volume16,923
Avg. volume76,740
Market cap9.5M
Beta (5Y monthly)1.62
PE ratio (TTM)N/A
EPS (TTM)-12.4200
Earnings date13 May 2024 - 18 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est26.00
  • GlobeNewswire

    Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

    EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

    EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant he

  • GlobeNewswire

    Hepion Pharmaceuticals to Present at NASH-TAG 2024

    EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is